Clinical Report: Evaluating the Predictive Value of 18F-FDG PET/CT in NSCLC

Overview

This meta-analysis evaluates the diagnostic utility of 18F-FDG PET/CT metabolic parameters in predicting major pathological response (MPR) after neoadjuvant therapy in non-small cell lung cancer (NSCLC). The study found high sensitivity and specificity for the metabolic parameter ΔSUVmax%, indicating its potential as a noninvasive tool for response assessment.

Background

Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading cause of cancer-related mortality globally. Accurate assessment of treatment response is crucial for optimizing patient management and guiding therapeutic decisions. 18F-FDG PET/CT has emerged as a valuable imaging modality for evaluating metabolic changes associated with neoadjuvant therapy in NSCLC.

Data Highlights

Key Findings

• ΔSUVmax% on 18F-FDG PET/CT has an sAUC of 0.96 for predicting MPR in NSCLC.
• SUVmax shows an sAUC of 0.95, indicating strong diagnostic performance.
• Pooled sensitivity and specificity for ΔSUVmax% are 0.87 and 0.93, respectively.
• Stratified analyses identified heterogeneity based on treatment regimen and sample characteristics.
• Quantitative metrics from 18F-FDG PET/CT may support individualized neoadjuvant strategies.

Clinical Implications

The findings suggest that metabolic parameters from 18F-FDG PET/CT can be effectively utilized to assess treatment response in NSCLC, potentially guiding clinical decision-making. Clinicians should consider incorporating these noninvasive metrics into their evaluation protocols to enhance patient management strategies.

Conclusion

The study highlights the high diagnostic performance of 18F-FDG PET/CT metrics in predicting pathological response after neoadjuvant therapy in NSCLC. Further high-quality research is needed to validate these findings and optimize their clinical application.

Related Resources & Content

1. European Radiology, 2025 -- Evaluating the Prognostic Significance of [18F]Fluorodeoxyglucose PET/CT in the Updated Staging Framework for Non-Small Cell Lung Cancer
2. European Radiology, 2024 -- Assessing Fluorine-18 Fluorodeoxyglucose ([18F]FDG) PET/CT Metabolic Metrics for Predicting PD-L1 Expression in Resectable Non-Small Cell Lung Cancer
3. European Radiology, 2024 -- Guidelines for Staging and Restaging in Oncology Using FDG-PET/CT: Recommendations from the European Society for Hybrid, Molecular, and Translational Imaging
4. European Radiology, 2023 -- Assessment of Metabolic Tumor and Lymph Node Response to Neoadjuvant Chemotherapy via FDG PET-CT as Indicators of Pathological Outcomes and Survival in Oesophageal Adenocarcinoma Patients
5. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer - PubMed, 2025
6. [18F]FDG PET/CT: EANM procedure guidelines for tumour imaging: version 3.0 - ScienceDirect, 2025
7. Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis | CoLab, 2025
8. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer - PubMed
9. [18F]FDG PET/CT: EANM procedure guidelines for tumour imaging: version 3.0 - ScienceDirect
10. Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis | CoLab